Cargando…

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

In the REWIND trial, dulaglutide reduced cardiovascular (CV) risk versus placebo in patients with type 2 diabetes in both the “established CV disease” (CVD) and “CV risk factor” subgroups. The SUSTAIN 6 and PIONEER 6 trials of semaglutide used different criteria for established CVD from those used i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verma, Subodh, Fainberg, Udi, Husain, Mansoor, Rasmussen, Søren, Rydén, Lars, Ripa, Maria Sejersten, Buse, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251906/ https://www.ncbi.nlm.nih.gov/pubmed/33606902 http://dx.doi.org/10.1111/dom.14360

Ejemplares similares

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
por: Strain, W. David, et al.
Publicado: (2022)

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
por: Husain, Mansoor, et al.
Publicado: (2022)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
por: Husain, Mansoor, et al.
Publicado: (2020)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
por: Nauck, Michael A., et al.
Publicado: (2021)

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2020)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
por: Rossing, Peter, et al.
Publicado: (2023)

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
por: Bain, Stephen C., et al.
Publicado: (2018)

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Rewinding the Molecular Clock: Looking at Pioneering Molecular Phylogenetics Experiments in the Light of Proteomics
por: Neely, Benjamin A., et al.
Publicado: (2021)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

RP rewind
Publicado: (2020)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
por: Thethi, Tina K., et al.
Publicado: (2020)

Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study
por: Dib, Anne, et al.
Publicado: (2022)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program
por: Srivastava, Kunal, et al.
Publicado: (2022)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
por: Dagenais, Gilles R., et al.
Publicado: (2020)

Editorial: Advanced Cardiovascular Imaging in Diabetes
por: Schick, Fritz, et al.
Publicado: (2022)

Unwinding and Rewinding: Double Faces of Helicase?
por: Wu, Yuliang
Publicado: (2012)

Rewinding the waves: tracking underwater signals to their source
por: Kadri, Usama, et al.
Publicado: (2017)

Mistreatment in Residency: Intervening With the REWIND Communication Tool
por: Pang, Joyce, et al.
Publicado: (2022)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
por: Buse, John B, et al.
Publicado: (2020)

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial
por: Prakash, Prashanth S, et al.
Publicado: (2022)

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
por: Aroda, Vanita R., et al.
Publicado: (2022)

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022)

Levorphanol: Rewinding an Old, Bygone Multimodal Opioid Analgesic!
por: Nair, Abhijit S, et al.
Publicado: (2019)

The reconsolidation using rewind study (RETURN): trial protocol
por: Astill Wright, Laurence, et al.
Publicado: (2021)

Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN‐6 to the real‐world type 2 diabetes population in the United Kingdom
por: Webb, Joanne, et al.
Publicado: (2021)

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

27 September 2013: Fast forward and rewind to our Origins
por: Antonella Del Rosso
Publicado: (2013)

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
por: Kosiborod, Mikhail N., et al.
Publicado: (2022)

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
por: Yabe, Daisuke, et al.
Publicado: (2022)

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t5goserkdhi3isqs17gljjgl3n